| 14.11.2024. THURSDAY HALL A | ||
| 08:00-09:15 | Special panel Cancer prevention and screening in Serbia – how can we do better? Moderators: Ivan Marković, Ana Jovićević |
|
| 08:00-08:15 | European Cancer Organization (ECO) screening activities and strategy for the future | Wim Ceelen, ECO |
| 08:15-08:25 | Cancer epidemiology in Serbia | Ana Jovićević (IORS) |
| 08:25-09:15 | Panel discussion: Ferenc Vicko (Ministry of Health), Verica Jovanović (Institute of Public Health “Dr Milan Jovanovic Batut”), Simona Borštnar (Slovenia), Tanja Španić (Europa Donna Slovenia) | |
| 09:15-09:30 | Coffee break | |
| 09:30-10:30 | Scientific session 1 Systemic treatment of breast cancer: novelties and dilemmas – part 1: HER2-positive breast cancer Moderators: Ljiljana Stamatović, Natalija Dedić Plavetić |
|
| 09:30-09:50 | HER2+ breast cancer systemic treatment | Javier Cortes |
| 09:50-10:30 | Panel discussion: Joseph Gligorov, Javier Cortes, Otto Metzger | |
| 10:30-10:45 | Coffee break | |
| 10:45-11:50 | Scientific session 2 Systemic treatment of breast cancer: novelties and dilemmas – part 2: HR-positive/HER2-negative breast cancer Moderators: Simona Borštnar, Snežana Šušnjar |
|
| 10:45-11:05 | Adjuvant chemotherapy for ER+ breast cancer: advances and a critical overview of therapy de-escalation | Otto Metzger |
| 11:05-11:50 | Panel discussion: Joseph Gligorov, Javier Cortes, Otto Metzger | |
| 11:50-12:10 | Coffee break | |
| 12:10-13:10 | Scientific session 3 Systemic treatment of breast cancer: novelties and dilemmas – part 3: Triple negative breast cancer Moderators: Ivana Božović Spasojević, Lazar Popović |
|
| 12:10-12:30 | Triple negative breast cancer systemic treatment | Ivana Božović Spasojević |
| 12:30-13:10 | Panel discussion: Joseph Gligorov, Javier Cortes, Otto Metzger | |
| 13:10-14:10 | Sponsored symposium – ROCHE Stepping Into The Spotlight: The Goal Is Cure. Revolution and Evolution of Therapy for Patients with HER2+ Breast Cancer (video material) Welcome and Introduction- Ivana Božović Spasojević Sharing HEReNA story- Ivana Božović Spasojević, Marijana Milović Kovačević, Lazar Popović Raising the bar for HER – PHERGain trial – Javier Cortes Panel discussion: Rewriting HER story – All participants Closing remarks – Ivana Božović Spasojević |
|
| 14:10-15:10 | Lunch | |
| 15:10-15:40 | Sponsored symposium – AstraZeneca Change is coming: Enhertu will write HER Destiny Moderator: Ivana Božović Spasojević Panelists: Lazar Popović, Natalija Dedić Plavetić, Simona Borštnar |
|
| 15:40-16:25 | Sponsored symposium – Novartis Evolution of HR+/HER2-breast cancer clinical practice Moderator: Lazar Popović Speakers: Marijana Milović Kovačević, Ana Cvetanović |
|
| 16:30-16:45 | Coffee break | |
| 16:45-18:15 | Sponsored symposium – ELI LILLY Expert Discussion on the CDK4/6i Choices in MBC & EBC Opening words from moderator – Lazar Popović Conducting Risk Assessment to Identify Patients with High-Risk HR+, HER2- EBC. Evolving Standards and Current Guidance – Marijana Milović Kovačević TREATMENT PARADIGM FOR HR+HER2- BREAST CANCER – Joseph Gligorov Managing Adverse Events and Improving Adherence/Persistence in High-Risk HR+, HER2- EBC – Snežana Šušnjar Analyzing the Latest Evidence on CDK4/6 Inhibitors in HR+, HER2- MB – Lazar Popović Panel discussion – all |
|
| Eli Lilly | ||
| 18:15-19:00 | Sponsored symposium – PFIZER Are we (RWE) ready? Discussion among experts Moderator: Lazar Popović Speakers: Lazar Popović, Sonja Martinović Šalinger, Ivana Božović, Ana Cvetanović |
|
| 14.11.2024. THURSDAY HALL B | ||
| 08:00-08:30 | Sponsored symposium – Johnson & Johnson How to achieve better tretment outcomes for patients with EGFR exon20ins mNSCLC? Why do we need novel therapies in EGFR exon20ins NSCLC? – Davorin Radosavljević Clinical study PAPILLON and CHRYSALIS – efficacy data – Bojan Zarić EGFR & MET dual inhibition – safety profile of bispecific antibody – Milica Kontić-Jovanović Panel discussion Davorin Radosavljević, Bojan Zarić, Milica Kontić-Jovanović |
|
| 08:30-13:30 | Lung Cancer Masterclass Organizers: Davorin Radosavljević, Bojan Zarić, Jelena Spasić |
|
| 08:30-09:15 | Lung Cancer Masterclass – part 1 Screening and early detection Moderators: Marko Jakopović, Goran Stojanović |
|
| 08:30-08:45 | Intro: Why should Lung Cancer screening be implemented? | Vladimir Stojšić |
| 08:45-08:55 | Hot topic: Real world data – Croatian experience | Marko Jakopović |
| 08:55-09:15 | Panel discussion: Rafal Dziadziuszko, Marko Jakopović, Davorin Radosavljević, Goran Stojanović, Bojan Zarić |
|
| 09:15-10:30 | Lung Cancer Masterclass – part 2 Advances in early stage non oncogene-addicted NSCLC Moderators: Davorin Radosavljević, Marko Jakopović |
|
| 09:15-09:25 | Intro: Moving therapy into early stage | Feđa Đorđević |
| 09:25-09:40 | New end-points in early-stage clinical trials | Jelena Spasić |
| 09:40-10:00 | Decision-making process in early stage non-oncogene addicted NSCLC: neoadjuvant vs. adjuvant vs. perioperative? | Sanjay Popat |
| 10:00-10:15 | Stage III beyond PACIFIC | Bojan Zarić |
| 10:15-10:30 | Panel discussion: Sanjay Popat, Bojan Zarić, Igor Gómez-Randulfe Rodríguez, Jelena Spasić, Rafal Dziadziuszko |
|
| 10:30-10:45 | Coffee break | |
| 10:45-12:15 | Lung Cancer Masterclass – part 3 Oncogene-addicted NSCLC Moderators: Jelena Spasić, Katja Mohorčić |
|
| 10:45-10:55 | Intro: Standard of care of EGFR and ALK positive NSCLC | Marko Jakopović |
| 10:55-11:10 | New treatment options for advanced EGFR mutated NSCLC | Urška Janžić |
| 11:10-11:25 | Advances in other/rare mutations (beyond EGFR and ALK) | Igor Gómez- Randulfe Rodríguez |
| 11:25-11:40 | Therapy sequencing and acquired resistance | Sanjay Popat |
| 11:40-11:55 | Adjuvant treatment of EGFR and ALK positive NSCLC | Davorin Radosavljević |
| 11:55-12:15 | Panel discussion: Davorin Radosavljevic, Sanjay Popat, Marko Jakopović, Urška Janžič, Igor Gómez-Randulfe Rodríguez |
|
| 12:15-12:30 | Coffee break | |
| 12:30-13:30 | Lung Cancer Masterclass – part 4 SCLC Moderators: Bojan Zarić, Urška Janžić |
|
| 12:30-12:40 | Intro: An area of unmet need or are we doing better in the treatment of SCLC? | Jelena Spasić |
| 12:40-12:55 | Radiotherapy in SCLC | Rafal Dziadziuszko |
| 12:55-13:10 | Advances in systemic therapy of SCLC | Katja Mohorčić |
| 13:10-13:30 | Panel discussion: Jelena Spasić, Rafal Dziadziuszko, Katja Mohorčič, Igor Gómez-Randulfe Rodríguez |
|
| 13:30-14:15 | Sponsored symposium – ROCHE New scenario Moderator: Bojan Zarić Futurospection – Bojan Zarić New roles – Bojan Zarić, Natalija Samardžić, Davorin Radosavljević Plot twist: Patient on the scene – Bojan Zarić, Natalija Samardžić, Davorin Radosavljević |
|
| 14:15-15:10 | Lunch | |
| 15:10-15:40 | Sponsored symposium – AstraZeneca EGFRevolution – 20Y of EGFm Expert perspectives and panel discussion Moderator: Bojan Zarić Panelists: Milica Kontić Jovanović, Radmila Janković, Nebojša Marić |
|
| 15:40-16:25 | Sponsored symposium – PFIZER Moderator: Bojan Zarić 1L lorlatinib in ALK+ NSCLC: 5 years later – Marko Jakopović Changing the conversation in 1L ALK+ NSCLC: Treatment decision-making – Bojan Zarić Our experience with Lorlatinib – Natalija Samardžić |
|
| 16:25-16:30 | Break | |
| 16:30-19:00 | ESSO Young Surgeons and Alumni Club (EYSAC) Research Academy Workshop, joined with Serbian Society of Surgical Oncology Organizers: Nada Santrač (EYSAC Chair), Wim Ceelen (EYSAC Research Academy senior lead) |
|
| 16:30-16:45 | ESSO & EYSAC: where are we now? | Nada Santrač |
| 16:45-17:00 | Disparities in cancer treatment | Johnn Henry Herrera Kok |
| 17:00-17:45 | Workshop part 1 Moderators: Nada Santrač, Nikolaos Vassos |
|
| 17:00-17:30 | How to start with translational and clinical research? | Wim Ceelen |
| 17:30-17:45 | Q&A | |
| 17:45-18:10 | Coffee break | |
| 18:10-18:55 | Workshop part 2 Moderators: Wim Ceelen, Milan Kocić |
|
| 18:10-18:40 | How to best use the RedCap platform for data acquisition and analysis? | Dara Lundon |
| 18:40-18:55 | Q&A | |
| 18:55-19:00 | Workshop take-home messages Wim Ceelen, Nada Santrač |
|